SCHEMBL1657973

SCHEMBL1657973

CCCCC(C)(C)CCO

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
LMNA P02545 3/20 0.41
TSHR P16473 3/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
HSD17B10 Q99714 1/20 0.41
FDPS P14324 1/20 0.34
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
FFAR1 O14842 1/20 0.32
CPT2 P23786 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
THRB P10828 1/20 0.31
HTT P42858 1/20 0.31
DNM1 Q05193 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1657127 0.92 SMN1; SMN2 (0.48) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL22748685 0.90 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL22748640 0.90 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL7645383 0.90 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL1658760 0.90 LMNA (0.50) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL1658861 0.89 SMN1; SMN2 (0.58) ALDH1A1SMN1; SMN2LMNATSHRMEN1
Ammonia Solution, Strong SCHEMBL27553300 0.87 LMNA (0.48) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL1658296 0.86 SMN1; SMN2 (0.55) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL8897968 0.85 TSHR (0.43) ALDH1A1SMN1; SMN2LMNATSHRMEN1
SCHEMBL588498 0.84 LMNA (0.57) ALDH1A1SMN1; SMN2LMNATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250248975-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SCHRODINGER, LLC 2025-08-07 US disclosed
CN-110894203-B Organic light-emitting compound, application thereof and organic electroluminescent device 北京绿人科技有限责任公司 2022-10-11 CN disclosed
EP-3191471-B1 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY ABBVIE DEUTSCHLAND (DE) 2020-03-11 EP disclosed
EP-3191471-A1 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2017-07-19 EP disclosed
US-9550754-B2 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy AbbVie Deutschland GmbH & Co. KG (DE) 2017-01-24 US disclosed
WO-2016038160-A1 4,5-DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2016-03-17 WO disclosed
US-20160075691-A1 4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY AbbVie Deutschland GmbH & Co. KG (DE) 2016-03-17 US disclosed
US-8632792-B2 Cooling sensation agent composition and sensory stimulation agent composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-01-21 US disclosed
US-20130131169-A1 COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-05-23 US disclosed
US-8377458-B2 Cooling sensation agent composition, sensory stimulation agent composition and use of the same TAKASAGO INTERNATIONAL CORPORATION (JP) 2013-02-19 US disclosed
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 US disclosed
US-20110081393-A1 COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME TAKASAGO INTERNATIONAL CORPORATION 2011-04-07 US disclosed
WO-2009123355-A2 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-10-08 WO disclosed
WO-2002022257-A1 CATALYST PRECURSOR FOR PRODUCING MALEIC ACID ANHYDRIDE BASF AKTIENGESELLSCHAFT (DE) 2002-03-21 WO disclosed
US-5366657-A Esters or ethers for electrooptical apparatus HOECHST AKTIENGESELLSCHAFT (DE) 1994-11-22 US disclosed
EP-0513069-A1 PROCESS FOR PRODUCING GEMINATE DIMETHYLALKYL COMPOUNDS AND THEIR USE IN LIQUID CRYSTALLINE MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1992-11-19 EP disclosed
WO-1991011441-A1 PROCESS FOR PRODUCING GEMINATE DIMETHYLALKYL COMPOUNDS AND THEIR USE IN LIQUID CRYSTALLINE MIXTURES HOECHST AKTIENGESELLSCHAFT (DE) 1991-08-08 WO disclosed
US-3979466-A ALKALI CATALYST CONTINENTAL OIL COMPANY (US) 1976-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TRPA1, HRH1, HRH2 ALDH1A1 520/4885SMN1; SMN2 2144/4885LMNA 1708/4885
US-20160075691-A1 4,5- DIHYDROPYRAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY SLC5A1, GFPT1, SULT2A1 ALDH1A1 571/4885SMN1; SMN2 3976/4885LMNA 4550/4885
US-20110081393-A1 COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME TRPA1, TRPV1, TRPM4 ALDH1A1 685/4885SMN1; SMN2 2797/4885LMNA 1727/4885
US-20130131169-A1 COOLING SENSATION AGENT COMPOSITION, SENSORY STIMULATION AGENT COMPOSITION AND USE OF THE SAME TRPA1, TRPV1, TRPM4 ALDH1A1 685/4885SMN1; SMN2 2797/4885LMNA 1727/4885
US-20250248975-A1 MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF CFTR, ABCB1, PKD1 ALDH1A1 3545/4885SMN1; SMN2 3610/4885LMNA 2396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.